Fetuin-A serum levels in patients with aortic aneurysms of Marfan syndrome and atherosclerosis

Szeberin, Zoltán; Fehérvári, Mátyás; Krepuska, Miklós; Apor, Astrid; Rimely, Endre; Sarkadi, Hunor; Bíró, G.; Sótonyi, Péter; Szepes, Zoltán; Prohászka, Zoltán; Kopper, László; Acsády, György

doi:10.1111/j.1365-2362.2010.02393.x

Cited by 8 publications

(8 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…High plasma triglycerides and a low high density lipoprotein level are responsible for the development of diabetic nephropathy and cardiovascular diabetic complications [21] . Fetuin‐A inhibits vascular calcification and its serum level is low in patients with atherosclerosis [22] . It acts as a new cardiovascular risk factor and its level is associated with intima‐media thickness [23] .…”

Section: Clinical Context Of Fetuin‐amentioning

confidence: 99%

See 1 more Smart Citation

Role of fetuin-A in atherosclerosis associated with diabetic patients

Singh¹,

Sharma²,

Garg³

et al. 2012

Journal of Pharmacy and Pharmacology

View full text Add to dashboard Cite

Objectives Fetuin-A is a circulating glycoprotein, formed in the liver. It regulates bone remodelling and calcium metabolism. Fetuin-A has adipogenic properties, so fat accumulation in the liver may be associated with higher levels of fetuin-A. Fetuin-A is an inhibitor of the phosphorylation of the insulin receptor tyrosine kinase. Key findings High concentrations of fetuin-A in humans causes insulin resistance. Insulin sensitivity is also found to be increased in fetuin-A knockout mice. Fetuin-A has been shown to cause insulin resistivity in type-2 diabetes mellitus and worsens the pro-atherogenic milieu. Summary Fetuin-A should be considered as a hepatic bio-marker. Vascular diseases like atherosclerosis are major causes of disability in patients with diabetes mellitus.

show abstract

Section: Clinical Context Of Fetuin‐amentioning

confidence: 99%

“…[21] Fetuin-A inhibits vascular calcification and its serum level is low in patients with atherosclerosis. [22] It acts as a new cardiovascular risk factor and its level is associated with intimamedia thickness. [23] The severity of atherosclerosis is inversely correlated with the fetuin-A level in serum.…”

Section: Structure Of Fetuin-amentioning

confidence: 99%

Role of fetuin-A in atherosclerosis associated with diabetic patients

Singh¹,

Sharma²,

Garg³

et al. 2012

Journal of Pharmacy and Pharmacology

View full text Add to dashboard Cite

show abstract

“…Low level is associated with increased intimal media thickness, apoptosis of vascular smooth muscle as well as vascular calcification which is associated with atherosclerosis. 15 This study revealed that the median serum level of Fetuin-A was significantly lower in psoriatic patients compared to control subjects.…”

Section: Discussionmentioning

confidence: 66%

Can Serum Fetuin-A be Used as a Marker for Cardiovascular Involvement in Psoriatic Patients?

Saleh

Sheha

Eskander

et al. 2023

Journal of Psoriasis and Psoriatic Arthritis

View full text Add to dashboard Cite

Background Psoriasis is a systemic inflammatory disorder. It is associated with increased risk of developing other chronic health diseases such cardiovascular disorders. Fetuin A is a glycoprotein that is present in blood serum. It may prevent vascular calcification by forming calciprotien particles; which are formed from their attachment with phosphate and calcium complexes. Aim The aim of this study was to measure serum Fetuin A in Psoriatic patients and correlate its level with cardiac events and risks in these patients using CT calcium (Ca) scoring. Patients and Methods 24 psoriatic patients (healthy without apparent cardiac risks to detect subclinical events if present) and 24 age and sex matched controls were tested for serum Fetuin A and underwent coronary calcium scoring by multidetector computed tomography (CT) scan. Psoriasis area and severity index (PASI) score for each patient was measured and was correlated with serum Fetuin A and CT calcium (Ca) scoring. Serum Fetuin A was compared between cases and controls and was correlated with coronary calcium score. Results There was highly statistically significant decrease in serum Fetuin A level in psoriatic group compared to control group ( P-value < .001). There was highly statistically significant negative correlation between calcium score and the level of serum Fetuin A ( P-value < .001). No statistically significant correlation was found between the serum level of Fetuin A and the psoriasis severity. Conclusion Serum Fetuin A is a simple, easy diagnostic tool to evaluate subclinical atherosclerosis in psoriatic patients

show abstract

“…Risk factors for atherosclerosis, including obesity, smoking, hyperlipidemia, and hypertension do not differ from the general population [104]. In addition, carotid intimal thickness, a surrogate measure for coronary artery disease, has been shown not to differ between Marfan syndrome and the general population [105]. Together, this data suggests that patients with Marfan syndrome should carry the same risk of atherosclerotic coronary artery disease as those without.…”

Section: Atherosclerotic Coronary Artery Diseasementioning

confidence: 81%

Features of Marfan syndrome not listed in the Ghent nosology – the dark side of the disease

Kodolitsch

Demolder

Girdauskas

et al. 2019

Expert Review of Cardiovascular Therapy

View full text Add to dashboard Cite

Introduction: The revised Ghent nosology presents the classical features of Marfan syndrome. However, behind its familiar face, Marfan syndrome hides less well-known features. Areas covered: The German Marfan Organization listed unusual symptoms and clinical experts reviewed the literature on clinical features of Marfan syndrome not listed in the Ghent nosology. Thereby we identified the following features: (1) bicuspid aortic valve, mitral valve prolapse, pulmonary valve prolapse, tricuspid valve prolapse, (2) heart failure and cardiomyopathy, (3) supraventricular arrhythmia, ventricular arrhythmia, and abnormal repolarization, (4) spontaneous coronary artery dissection, anomalous coronary arteries, and atherosclerotic coronary artery disease, tortuosity-, aneurysm-, and dissection of large and medium-sized arteries, (5) restrictive lung disease, parenchymal lung disease, and airway disorders, (6) obstructive-and central sleep apnea, (7) liver and kidney cysts, biliary tract disease, diaphragmatic hernia, and adiposity, (8) premature labor, and urinary incontinence, (9) myopathy, reduced bone mineral density, and craniofacial manifestations, (10) atrophic scars, (11) caries, and craniomandibular dysfunction, (12) headache from migraine and spontaneous cerebrospinal fluid leakage, (13) cognitive dysfunction, schizophrenia, depression, fatigue, and pain, (14) and activated fibrinolysis, thrombin, platelets, acquired von Willebrand disease, and platelet dysfunction. Expert commentary: Future research, nosologies, and guidelines may consider less well-known features of Marfan syndrome. ARTICLE HISTORY

show abstract

Fetuin-A serum levels in patients with aortic aneurysms of Marfan syndrome and atherosclerosis

Abstract: The significantly lower serum level of fetuin-A in the atherosclerotic aneurysm group supports the protective role of fetuin-A in the evolution of arterial calcification.

Cited by 8 publications

References 33 publications

Role of fetuin-A in atherosclerosis associated with diabetic patients

Role of fetuin-A in atherosclerosis associated with diabetic patients

Can Serum Fetuin-A be Used as a Marker for Cardiovascular Involvement in Psoriatic Patients?

Features of Marfan syndrome not listed in the Ghent nosology – the dark side of the disease

Contact Info

Product

Resources

About